Naturally occurring N 6 -substituted adenosines (cytokinin ribosides) are in vitro inhibitors of platelet aggregation: An in silico evaluation of their interaction with the P2Y 12 receptor

Naturally occurring N 6 -substituted adenosines (cytokinin ribosides) are in vitro inhibitors of platelet aggregation: An in silico evaluation of their interaction with the P2Y 12 receptor Lipophilic Modifications to Dinucleoside Polyphosphates and Nucleotides that Confer Antagonist Properties at the Platelet P2Y₁₂ Receptor P2Y12 antagonists: Approved drugs, potential naturally isolated and synthesised compounds, and related in-silico studies Synthesis and in vitro stability of nucleoside 5′-phosphonate derivatives Effects of 5‘-Phosphate Derivatives of 2-Hexynyl Adenosine and 2-Phenylethynyl Adenosine on Responses of Human Platelets Mediated by P2Y Receptors Discovery of 4-Aryl-7-Hydroxyindoline-Based P2Y₁ Antagonists as Novel Antiplatelet Agents Novel Arylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-Dioxides as Inhibitors of Platelet Aggregation. 1. Synthesis and Pharmacological Evaluation New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors Nucleoside alkaloids with anti-platelet aggregation activity from the rhizomes of Ligusticum striatum Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y₁₂ Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283